Animalcare Group plc

ANCR.UK

$2.99

Closing

0.00

1D

▲38.82%

YTD

Market cap

$180.17M

52 week high

$3.17

52 week low

$2.03

Volume

6,164

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$180.17M

Analysts' Rating

BUY

Price Target (Mean)

Unable to collect data for some field(s).

Total Analysts

0

P/E

120.10

Operating Margin

0.00%

Beta

0.78

Revenue Growth (Annual)

-

52 week high

$3.17

52 week low

$2.03

Div. Yield

2.12%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Animalcare Group plc is a United Kingdom-based international veterinary sales and marketing company. The Company is focused on bringing products to market through its own development pipeline, partnerships and through acquisitions. The Company develops and commercializes prescription and over-the-counter pharmaceutical products that improve animal health and wellbeing. These are developed in-house, acquired from other companies or in-licensed from its partners. The Company manages an international supply chain, including specialist veterinary wholesalers and distributors. It partners with companies to commercialize products across Europe. The Company operates in three categories within the veterinary market: companion animals, equine and other, and production animals. Its product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs. The Company operates in seven countries and exports to about 40 countries in Europe and worldwide.